$LXEO News

Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout

Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy - Slideshow

Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy

Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy Transcript

Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM

Lexeo Therapeutics to Participate in the Chardan Healthcare Conference

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript

Lexeo Therapeutics, Inc. (LXEO) Mantle Therapeutics Inc. - M&A Call - Slideshow

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

Lexeo Therapeutics Q2 EPS $(0.30) Misses $(0.28) Estimate

Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy

What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple

Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update?

Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript

JP Morgan Maintains Overweight on Lexeo Therapeutics, Lowers Price Target to $9

Lexeo Therapeutics's LX2006 Has A Viable Regulatory Pathway And Timeline